The reason I have not published in a while is because my husband fell and was hospitalized. He has now been released by the NHS. US stocks declined as I anticipated, but European and British ones are buoyant.
Israeli Compugen (CGEN) and its backer Astra Zeneca (AZN) are up on news that CGEN's bi-specific antigen TIGIT is moving to clinical trials in lung cancer.
Chicago is getting bigger with CME bidding $16 mn in stocks for our holding in CBOE.
Miner BHP will end its UK listing and only trade directly in Oz.
BiolineRx (BLRX) earned minus 15 cents in the last quarter but its stem cell collection system for transplant in myeloma cancers which improves volume looks like a winner, called Motiafortide. It is also Israeli.
Views of Nio (NIO) the Chinese carmaker are mixed as Beijing is now cracking down on the corporate rich as part of its return to communism. It aims to sell cheaper electric cars in the mass market starting in the current quarter to be more leftish.
We will be spending a further week in London than originally planned because of my husband's illness. I am doing my best but these matters are more important than blogs
Comments
Log in or sign up to join the conversation.